
United Therapeutics Announces First UThymoKidney Xenotransplant in EXTEND Clinical Trial for Patients with End-Stage Renal Disease
United Therapeutics Corporation, a public benefit corporation focused on developing innovative therapies and technologies for serious medical conditions, has announced the first clinical xenotransplantation procedure in its EXTEND clinical study of UThymoKidney™. The investigational kidney was transplanted into a patient with end-stage renal disease (ESRD) at NYU Langone Health, marking a significant development in the clinical advancement of xenotransplantation.
The first transplant represents an important step in United Therapeutics’ broader efforts to address the critical shortage of donor organs through the development of manufactured organs derived from genetically modified animals. The EXTEND study is designed to evaluate whether the investigational UThymoKidney can provide a safe and effective treatment option for individuals with advanced kidney disease who have limited access to conventional kidney transplantation.
Kidney transplantation remains one of the most effective treatment options for eligible patients with end-stage renal disease. However, the availability of suitable donor organs continues to fall substantially short of clinical demand. Many patients spend years waiting for a compatible kidney, while others may experience significant health deterioration or die before a suitable organ becomes available. Through its xenotransplantation program, United Therapeutics aims to develop an additional source of transplantable organs that could help address this longstanding challenge.
The EXTEND study is part of the company’s continued investment in xenotransplantation research, organ manufacturing technologies, and the development of genetically engineered animal organs for human transplantation.
EXTEND Study Targets Patients with Limited Kidney Transplant Options
The ongoing EXTEND clinical study will assess the safety and efficacy of UThymoKidney in patients diagnosed with end-stage renal disease who face significant barriers to receiving a conventional kidney transplant.
The study is intended for two primary patient populations. The first includes individuals who are not eligible for conventional allogeneic kidney transplantation. The second includes patients who are listed on the kidney transplant waiting list maintained by the Organ Procurement and Transplantation Network (OPTN), but whose clinical circumstances indicate that they are more likely to die or remain without a transplant within five years than receive a donor kidney.
These patient populations represent individuals with substantial unmet medical needs. Although kidney transplantation can significantly improve survival and quality of life for many people with kidney failure, access to transplantation remains limited by the availability of suitable donor organs, medical eligibility requirements, and the lengthy waiting periods associated with organ allocation.
For patients who cannot receive conventional transplantation, long-term dialysis may remain the primary available treatment. While dialysis can support essential kidney functions, it requires ongoing medical care and can place considerable physical, emotional, and financial burdens on patients and their families.
By evaluating UThymoKidney in a carefully selected patient population, the EXTEND study seeks to determine whether xenotransplantation could eventually offer another treatment pathway for people who have few or no conventional transplant options.
The study will generate clinical evidence regarding the safety and potential therapeutic benefits of transplanting a genetically modified porcine kidney containing thymic tissue into human recipients. Its findings will help inform the future development of xenotransplantation as a potential approach to addressing the global shortage of donor organs.
UThymoKidney Incorporates Porcine Thymic Tissue to Address Organ Rejection
UThymoKidney is an investigational xenokidney developed using a genetically modified pig. The organ incorporates porcine thymic tissue, which is intended to help condition the recipient’s immune system to recognize the transplanted kidney as part of the body and potentially reduce the likelihood of immune-mediated organ rejection.
One of the most significant challenges in xenotransplantation is the human immune system’s natural response to organs derived from other species. When an animal organ is transplanted into a human recipient, the immune system may recognize specific molecules on the surface of the transplanted tissue as foreign. This recognition can trigger an immune response that may lead to rapid or severe organ rejection.
United Therapeutics has incorporated a specific genetic modification into the donor pig to address one of the major biological barriers associated with pig-to-human organ transplantation.
The investigational UThymoKidney is derived from a pig with a single gene edit. This modification involves the inactivation of the gene responsible for producing alpha-gal, a sugar molecule found on the surface of cells in many mammals, including pigs.
Alpha-gal is particularly important in xenotransplantation because humans naturally possess antibodies that can recognize this molecule. When an organ containing alpha-gal is introduced into the human body, these antibodies may trigger an immediate immune response, potentially resulting in rapid rejection of the transplanted organ.
By inactivating the gene responsible for alpha-gal synthesis, United Therapeutics aims to reduce this initial immune reaction and improve the biological compatibility of the porcine kidney with human recipients.
In addition to the genetic modification, UThymoKidney incorporates porcine thymic tissue, which is intended to play a complementary role in immune system adaptation.
The thymus is an important organ involved in the development and education of T cells, a major component of the adaptive immune system. Thymic tissue helps the immune system distinguish between the body’s own tissues and foreign substances. By incorporating pig-derived thymic tissue into the investigational kidney, the company aims to encourage immune tolerance toward the transplanted organ.
This approach is intended to help the recipient’s immune system recognize the xenokidney as self rather than as foreign tissue, potentially reducing the risk of rejection.
The combination of genetic engineering and thymic tissue represents an important element of United Therapeutics’ strategy to develop transplantable animal organs that may be more compatible with human recipients.
However, the safety and effectiveness of this approach must be established through clinical investigation. The EXTEND study will provide an opportunity to evaluate the performance of UThymoKidney in patients with advanced kidney disease and generate evidence to guide further research and development.
United Therapeutics Highlights Progress in Xenotransplantation Development
Commenting on the first clinical transplant, Jayme Locke, M.D., Ph.D., Chief Medical Officer, Xenotransplantation at United Therapeutics, described the milestone as an important moment for both the company and the broader xenotransplantation field.
“Today marks an exciting moment for United Therapeutics and for the field of xenotransplantation. EXTEND is the second clinical trial in our xeno-organ manufacturing program, and it reflects years of investment in the science, facilities, and regulatory groundwork needed to bring this technology from possibility to clinical reality,” Locke said.
The company’s progress reflects its continued commitment to advancing xenotransplantation from experimental research toward clinical applications. Developing animal-derived organs for human transplantation requires extensive scientific research, specialized manufacturing capabilities, genetic engineering expertise, and regulatory preparation.
United Therapeutics has been investing in these areas to establish the infrastructure required to manufacture organs that could potentially be used in clinical settings.
The initiation of the EXTEND study represents another stage in this development process, allowing the company to move beyond laboratory research and evaluate its investigational technology in human patients under a structured clinical framework.
Locke’s comments also highlight the importance of conducting xenotransplantation research through carefully designed clinical studies that prioritize patient safety while examining the potential benefits of genetically modified organs.
The company’s xeno-organ manufacturing program is intended to establish a more reliable and scalable approach to organ production, potentially reducing dependence on the limited supply of human donor organs.
Company Emphasizes Patient Safety and Scientific Development
Leigh Peterson, Ph.D., Executive Vice President, Product Development and Xenotransplantation at United Therapeutics, also highlighted the significance of the first transplant and the company’s long-term development strategy.
“We are demonstrating that an investigational manufactured organ program can move methodically from the laboratory to patients, always with patient safety first. We are deeply grateful to the participant, their family, and the NYU Langone team,” Peterson said.
The statement underscores the importance of collaboration among biotechnology companies, clinical researchers, transplant surgeons, and participating patients in advancing complex medical technologies.
Xenotransplantation requires extensive coordination across multiple areas, including organ development, genetic modification, transplant procedures, immunological management, and post-transplant monitoring.
The first procedure in the EXTEND study demonstrates the transition of United Therapeutics’ research and manufacturing capabilities into a clinical setting. The company is seeking to establish a scientific foundation for evaluating manufactured xenokidneys and determining whether they can become a viable option for patients who cannot access conventional transplantation.
Patient safety remains a central consideration as the study progresses. Clinical evaluation will be essential to understanding the potential risks associated with animal-derived organs, including immune reactions, organ rejection, and other complications that may arise following transplantation.
The participation of NYU Langone Health also reflects the importance of specialized transplant centers in conducting pioneering clinical research and evaluating emerging transplantation technologies.
NYU Langone Highlights the Urgent Need for Alternative Organ Sources
Robert Montgomery, M.D., D.Phil., the H. Leon Pachter, M.D., Professor of Surgery; Chair of the Department of Surgery at NYU Grossman School of Medicine; and Director of the NYU Langone Transplant Institute, led the surgical team responsible for performing the first xenotransplant in the EXTEND study.
Montgomery emphasized the urgent need for additional organ sources to address the shortage of kidneys available for transplantation.
“Every day, people with kidney failure die waiting for an organ that never comes. The need for new sources of organs is urgent. UThymoKidney is designed with the intention to help a recipient’s immune system accept the organ and reduce the risk of organ rejection. The EXTEND study provides a carefully designed, scientifically rigorous way to determine whether another approach to xenotransplantation can deliver real benefit to patients who have few other options,” Montgomery said.
His comments highlight the significant challenges faced by patients with ESRD who are waiting for kidney transplantation. The shortage of suitable donor kidneys continues to create substantial pressure on transplant programs and healthcare systems.
For patients with advanced kidney failure, receiving a transplant can offer important benefits compared with remaining on long-term dialysis. However, not all patients are medically eligible for transplantation, and others face prolonged waiting periods that may affect their overall health and survival.
The development of alternative organ sources could potentially help expand transplantation opportunities and provide additional treatment options for individuals who are unlikely to receive a conventional donor kidney.
Through the EXTEND study, United Therapeutics and NYU Langone Health are evaluating whether UThymoKidney’s design can address some of the immunological challenges that have historically limited the clinical application of xenotransplantation.
Xenotransplantation Could Represent a New Approach to Organ Manufacturing
Xenotransplantation involves transplanting living cells, tissues, or organs from one species into another. In recent years, advances in genetic engineering, immunology, and organ manufacturing have increased scientific interest in using genetically modified pigs as potential sources of human transplant organs.
Pigs are considered promising candidates for xenotransplantation because their organs have anatomical and physiological characteristics that make them suitable for investigation as potential alternatives to human donor organs.
Nevertheless, significant scientific and clinical challenges remain. These include immune rejection, blood compatibility, inflammatory responses, long-term organ function, and the potential transmission of animal-derived infectious agents.
Genetic modifications and innovative immune-tolerance strategies are being investigated to address these challenges and improve the feasibility of pig-to-human transplantation.
United Therapeutics’ UThymoKidney program combines a single-gene modification designed to eliminate alpha-gal production with the inclusion of porcine thymic tissue intended to support immune acceptance.
The EXTEND study will help determine whether this approach can provide meaningful clinical benefits for patients with severe kidney disease who have limited treatment alternatives.
A Significant Milestone in United Therapeutics’ Clinical Program
The first UThymoKidney transplant in the EXTEND study represents an important milestone in United Therapeutics’ broader xenotransplantation strategy. It also marks the company’s continued progression in developing manufactured organs as potential solutions to the shortage of transplantable human organs.
As the clinical study continues, the evaluation of safety and efficacy will be essential to determining the future role of UThymoKidney in kidney transplantation. The clinical experience generated through EXTEND may also contribute to a broader understanding of how genetic engineering and immune-conditioning strategies can improve the compatibility of animal-derived organs with human recipients.
For patients with end-stage renal disease who are unable to receive conventional donor kidneys, advances in xenotransplantation could eventually create new possibilities for treatment.
Although UThymoKidney remains investigational and its clinical benefits have yet to be established, the completion of the first transplant demonstrates progress in translating years of research, manufacturing development, and regulatory preparation into human clinical investigation.
Through its collaboration with NYU Langone Health, United Therapeutics is advancing the EXTEND study to assess whether its genetically modified porcine kidney technology can become another potential approach to addressing the critical shortage of donor organs.
The study represents another step toward the long-term goal of expanding access to transplantation through the development of alternative, manufactured organ sources for patients with serious and life-threatening conditions.
About United Therapeutics’ Xenotransplantation Program
United Therapeutics is advancing clinical trials called EXTEND, EXPAND, and EXPRESS, which are intended to support Biologics License Applications (BLA) with the U.S. Food and Drug Administration (FDA) for each of its three investigational xenotransplantation products:
EXTEND is a multicenter, open-label, combination phase 1/2/3 clinical trial designed to evaluate the safety and efficacy of UThymoKidney. This phaseless trial will progress without separate phase 1, 2, and 3 studies typically associated with conventional drug approvals.
Study participants will receive a UThymoKidney transplant followed by a 24-week post-transplant follow-up period, including the evaluation of all study endpoints and safety assessments. After the 24-week post-transplant follow-up period, participants who receive a UThymoKidney will continue to be followed for the rest of their lives, including monitoring for UThymoKidney function and zoonotic infections.
Efficacy endpoints include participant survival rate, UThymoKidney survival rate, change in measured glomerular filtration rate1, donor specific hyporesponsiveness2, and change in quality of life3 in participants at 24 weeks post-transplant, as well as overall survival time of participants receiving a UThymoKidney and overall survival time of the UThymoKidney post-transplant. Safety endpoints include the incidence of adverse events and serious adverse events, all-cause mortality, and the incidence of proteinuria4, zoonotic infections, and opportunistic infections5.
The first six transplants will take place at two centers, with a 12-week waiting period between the first and second transplants. After all six participants reach at least 12 weeks post-transplant, safety and efficacy data will be reviewed by an Independent Data Monitoring Committee to determine if the study should continue. United Therapeutics intends to present the data from the first six transplants to the FDA for review prior to including additional transplant centers and increasing the study sample size to support a BLA. Additional details on the EXTEND study, including full inclusion and exclusion criteria, are available at ClinicalTrials.gov.
EXPAND is a multicenter, open-label, safety and efficacy study of United Therapeutics’ UKidney™ in patients with ESRD. The EXPAND study is currently being conducted at NYU Langone Health and Northwestern Medicine, with the potential to include other centers if initial data are supportive. EXPAND is the world’s first clinical trial designed specifically to generate the definitive safety and efficacy data needed to support an application for regulatory approval (i.e., a registration study).
EXPRESS is an open-label, safety and efficacy study of United Therapeutics’ UHeart™ in patients with advanced heart failure. It will start at a single center with potential to include other centers if initial data are supportive.
The UThymoKidney is a xenokidney that contains porcine thymic tissue and is derived from a pig with a single gene edit.
The UKidney and UHeart are derived from a pig with 10 gene edits. Six human genes are added to the pig genome to facilitate immunological acceptance and compatibility of the organ in the human recipient. Four porcine genes are inactivated or “knocked out” to reduce the risk of organ rejection and to moderate organ growth.
United Therapeutics’ xeno-organs are all investigational-stage products which have not been approved in any jurisdiction for any indication.
The Organ Shortage Crisis and ESRD
Demand for organ transplants far exceeds the supply of available organs, and alternative organ sources are needed. In the United States alone, there are approximately 830,000 patients with kidney failure, over 550,000 patients on dialysis, and more than 90,000 patients on the kidney transplant waiting list. Only about 22,000 deceased donor kidney transplants occurred in 20256. The 2024 US Renal Data System Annual Report found that, three years after starting dialysis, only 12% of patients had been placed on an OPTN kidney transplant waitlist and more than 40% had died without receiving a kidney transplant7. Xenotransplantation offers the potential to mitigate, and perhaps even solve, the organ shortage crisis.
About United Therapeutics
Founded by CEO Martine Rothblatt to discover a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.



